# Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

> **NCT00071084** · PHASE2 · COMPLETED · sponsor: **Genmab** · enrollment: 22 (actual)

## Conditions studied

- Cutaneous T-Cell Lymphoma

## Interventions

- **DRUG:** HuMax-CD4
- **DRUG:** HuMax-CD4

## Key facts

- **NCT ID:** NCT00071084
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05-27
- **Primary completion:** 2004-06-29
- **Final completion:** 2004-06-29
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00071084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00071084, "Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00071084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*